Elixiron Immunotherapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Elixiron Immunotherapeutics's estimated annual revenue is currently $3.3M per year.
- Elixiron Immunotherapeutics's estimated revenue per employee is $155,000
Employee Data
- Elixiron Immunotherapeutics has 21 Employees.
- Elixiron Immunotherapeutics grew their employee count by -9% last year.
Elixiron Immunotherapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Elixiron Immunotherapeutics?
Elixiron employs advances in translational medicine to identify targets from clinical observations, and various drug modalities including biologics derived from a proprietary single human B cell cloning platform to develop innovative therapies for malignant, immunological and degenerative diseases. Our lead pipeline candidates are EI-1071, a small molecule inhibitor of CSF1R kinase activity being explored as a potential therapy for Alzheimer's disease and to improve cancer immunotherapy by reducing immune suppression in tumors, and EI-001, a monoclonal antibody being investigated for treatment of chronic Hepatitis B and Vitiligo.
keywords:N/A
N/A
Total Funding
21
Number of Employees
$3.3M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Taipei
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.6M | 25 | 19% | N/A |
#2 | $2.4M | 26 | 13% | N/A |
#3 | $4.3M | 28 | -12% | N/A |
#4 | $8.1M | 29 | 4% | N/A |
#5 | $4.3M | 29 | 12% | N/A |